Korro Bio (KRRO) vs Oramed Pharmaceuticals (ORMP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Korro Bio (KRRO) has outperformed Oramed Pharmaceuticals (ORMP) over the past year, gaining 93.9% versus a gain of 38.4%. Over five years, ORMP leads with a -82.3% price change compared with -95.7% for KRRO. Korro Bio is the larger company by market cap ($167.2 million vs $155.2 million), about 1.1 times the size.
Oramed Pharmaceuticals converts more of its revenue into profit, with a net margin of 3202.5% versus -1834.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRRO | ORMP |
|---|---|---|
| Share price | $12.18 | $3.57 |
| Market cap | $167.18M | $155.24M |
| 1-day change | -0.08% | -3.25% |
| YTD return | +52.06% | +25.26% |
| 1-year return | +93.95% | +38.37% |
| 5-year return | -95.67% | -82.34% |
| P/E ratio (TTM) | — | 1.05 |
| EPS (TTM) | $-8.89 | $3.41 |
| Dividend yield | 0.00% | 7.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.39M | $2.00M |
| Revenue growth (YoY) | +181.46% | — |
| Net income (latest FY) | $-117.26M | $64.05M |
| Gross margin | — | 0.65% |
| Operating margin | -1906.37% | -754.40% |
| Net margin | -1834.48% | 3202.50% |
| 52-week high | $17.35 | $5.47 |
| 52-week low | $5.20 | $2.52 |
| Distance from 52-week high | -29.81% | -34.73% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +76.52% | +96.08% |
| Average volume | 186.03K | 173.38K |
| Shares outstanding | 13.73M | 43.49M |
| Employees | 58 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRRO has outperformed ORMP by 55.6 percentage points over the past year.
- Oramed Pharmaceuticals offers a meaningfully higher dividend yield (7.00% vs 0.00%).
- Oramed Pharmaceuticals is more profitable, keeping 3202.5 cents of every revenue dollar as net income versus -1834.5 cents for Korro Bio.
About Korro Bio
KRRO stock →Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About Oramed Pharmaceuticals
ORMP stock →Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
Health Care · Biotechnology: Pharmaceutical Preparations
KRRO vs ORMP FAQ
Which is bigger, Korro Bio or Oramed Pharmaceuticals?
Korro Bio (KRRO) is larger, with a market capitalization of $167.18M compared with $155.24M for Oramed Pharmaceuticals (ORMP).
Which stock has performed better over the past year, KRRO or ORMP?
KRRO returned +93.95% over the past 12 months, compared with +38.37% for ORMP (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Korro Bio or Oramed Pharmaceuticals?
Oramed Pharmaceuticals pays a dividend yielding 7.00%, while Korro Bio does not currently pay a regular dividend.
Are Korro Bio and Oramed Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.